BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229-361. [PMID: 36017568 DOI: 10.1093/eurheartj/ehac244] [Cited by in Crossref: 124] [Cited by in F6Publishing: 100] [Article Influence: 124.0] [Reference Citation Analysis]
Number Citing Articles
1 Fukumitsu M, Ariyasu R, Ishiyama M, Mochizuki T, Takeda K, Ono M, Oyakawa T, Ebihara A, Nishizawa A, Tomomatsu J, Kogawa T, Kitano S, Shiga T. Myocarditis associated with immune-checkpoint inhibitors diagnosed by cardiac magnetic resonance imaging. Int Cancer Conf J 2023;12:109-14. [PMID: 36896200 DOI: 10.1007/s13691-022-00588-1] [Reference Citation Analysis]
2 Giordani AS, Candelora A, Fiacca M, Cheng C, Barberio B, Baritussio A, Marcolongo R, Iliceto S, Carturan E, De Gaspari M, Rizzo S, Basso C, Tarantini G, Savarino EV, Alp C. Myocarditis and inflammatory bowel diseases: A single-center experience and a systematic literature review. Int J Cardiol 2023;376:165-71. [PMID: 36738845 DOI: 10.1016/j.ijcard.2023.01.071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Butel-Simoes LE, Haw TJ, Williams T, Sritharan S, Gadre P, Herrmann SM, Herrmann J, Ngo DTM, Sverdlov AL. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation. Hypertension 2023;80:685-710. [PMID: 36756872 DOI: 10.1161/HYPERTENSIONAHA.122.17947] [Reference Citation Analysis]
4 Camilli M, Skinner R, Iannaccone G, La Vecchia G, Montone RA, Lanza GA, Natale L, Crea F, Cameli M, Del Buono MG, Lombardo A, Minotti G. Cardiac Imaging in Childhood Cancer Survivors: A State-of-the-Art Review. Curr Probl Cardiol 2023;48:101544. [PMID: 36529231 DOI: 10.1016/j.cpcardiol.2022.101544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Alfaris I, Asselah J, Aziz H, Bouganim N, Mousavi N. The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer. Curr Atheroscler Rep 2023;25:145-54. [PMID: 36848014 DOI: 10.1007/s11883-023-01085-3] [Reference Citation Analysis]
6 Martins Carvalho M, Alves Pinto R, Proença T, Costa I, Tavares N, Paiva M, Sousa C, Macedo F. Cardiovascular toxicity in breast cancer patients – contributors and role of cardioprotective drugs. Monaldi Arch Chest Dis 2023. [DOI: 10.4081/monaldi.2023.2514] [Reference Citation Analysis]
7 Salakheeva EY, Shchendrygina AA, Sokolova IY, Zhbanov KA, Tsatsurova SA, Kanevskiy NI, Muzychenko YN, Kardanova SA, Stebakova VO, Privalova EV, Kulagina TY, Bulkina OA, Ilgisonis IS, Belenkov YN. Correlation between the level of C-reactive protein and the parameters of the functional status of the left atrium in patients with lymphoproliferative diseases against the background of chemotherapy. jour 2023;101:55-62. [DOI: 10.30629/0023-2149-2023-101-1-55-62] [Reference Citation Analysis]
8 Liu Y. A novel cardio-oncology service line model in optimizing care access, quality and equity for large, multi-hospital health systems. Cardiooncology 2023;9:16. [PMID: 36973756 DOI: 10.1186/s40959-023-00167-0] [Reference Citation Analysis]
9 Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH; Writing Committee. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2023;81:1076-126. [PMID: 36697326 DOI: 10.1016/j.jacc.2022.11.022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wang D, Bauersachs J, Berliner D. Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. Biology (Basel) 2023;12:472. [PMID: 36979163 DOI: 10.3390/biology12030472] [Reference Citation Analysis]
11 Mohammad KO, Fanous H, Vakamudi S, Liu Y. Refractory right ventricular myocarditis induced by immune checkpoint inhibitor despite therapy cessation and immune suppression. Cardiooncology 2023;9:15. [PMID: 36941689 DOI: 10.1186/s40959-023-00165-2] [Reference Citation Analysis]
12 Lisi DM. Comment on: AGS And NIA bench-to bedside conference summary: Cancer and cardiovascular disease. J Am Geriatr Soc 2023. [PMID: 36929848 DOI: 10.1111/jgs.18332] [Reference Citation Analysis]
13 Marar RI, Abbasi MA, Prathivadhi-Bhayankaram S, Acevedo AD, Villarraga H, Anavekar N, Bhatt VR, Paludo J. Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncol Pract 2023;:OP2200713. [PMID: 36930845 DOI: 10.1200/OP.22.00713] [Reference Citation Analysis]
14 Yang L, Zhang N, Yue Q, Song W, Zheng Y, Huang S, Qiu J, Tse G, Li G, Wu S, Liu T. Long-term atherosclerotic cardiovascular disease risk in patients with cancer: a population-based study. Current Problems in Cardiology 2023. [DOI: 10.1016/j.cpcardiol.2023.101693] [Reference Citation Analysis]
15 Chen JZ, Liang B. Comparison of American and European guidelines for cardio-oncology of heart failure. Heart Fail Rev 2023. [PMID: 36912998 DOI: 10.1007/s10741-023-10304-7] [Reference Citation Analysis]
16 Forsyth P, Beezer J, Bateman J. Holistic approach to drug therapy in a patient with heart failure. Heart 2023:heartjnl-2022-321764. [PMID: 36898707 DOI: 10.1136/heartjnl-2022-321764] [Reference Citation Analysis]
17 Mauro C, Capone V, Cocchia R, Cademartiri F, Riccardi F, Arcopinto M, Alshahid M, Anwar K, Carafa M, Carbone A, Castaldo R, Chianese S, Crisci G, D’assante R, De Luca M, Franzese M, Galzerano D, Maffei V, Marra AM, Valente V, Giardino F, Mazza A, Ranieri B, D’agostino A, Rega S, Romano L, Scagliarini S, Sepe C, Vriz O, Izzo R, Cittadini A, Bossone E, Salzano A. Cardiovascular Side Effects of Anthracyclines and HER2 Inhibitors among Patients with Breast Cancer: A Multidisciplinary Stepwise Approach for Prevention, Early Detection, and Treatment. JCM 2023;12:2121. [DOI: 10.3390/jcm12062121] [Reference Citation Analysis]
18 Cuomo G, Iannone FP, Di Lorenzo A, Testa C, Ciccarelli M, Venturini E, Cesaro A, Pacileo M, Tagliamonte E, D'Andrea A, Vecchione C, Vigorito C, Giallauria F. Potential Role of Global Longitudinal Strain in Cardiac and Oncological Patients Undergoing Cardio-Oncology Rehabilitation (CORE). Clin Pract 2023;13:384-97. [PMID: 36961060 DOI: 10.3390/clinpract13020035] [Reference Citation Analysis]
19 Wang T, Carrier M. Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management. Current Oncology 2023;30:3032-3046. [DOI: 10.3390/curroncol30030230] [Reference Citation Analysis]
20 Kandels J, Metze M, Hagendorff A, Marshall RP, Hepp P, Laufs U, Stöbe S. The impact of upright posture on left ventricular deformation in athletes. Int J Cardiovasc Imaging 2023. [PMID: 36869240 DOI: 10.1007/s10554-023-02820-2] [Reference Citation Analysis]
21 Zheng Y, Huang S, Xie B, Zhang N, Liu Z, Tse G, Liu T. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy. Curr Probl Cardiol 2023;48:101536. [PMID: 36481392 DOI: 10.1016/j.cpcardiol.2022.101536] [Reference Citation Analysis]
22 Dong M, Yu T, Tse G, Lin Z, Lin C, Zhang N, Wang R, Liu T, Zhong L. PD-1/PD-L1 Blockade Accelerates the Progression of Atherosclerosis in Cancer Patients. Curr Probl Cardiol 2023;48:101527. [PMID: 36455793 DOI: 10.1016/j.cpcardiol.2022.101527] [Reference Citation Analysis]
23 Barac A, López-Fernández T. An Inconvenient Truth About the LVEF and Cardiac Monitoring in Oncology: Please Don't Shoot the Messenger! JACC Cardiovasc Imaging 2023;16:279-81. [PMID: 36752437 DOI: 10.1016/j.jcmg.2022.11.017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Slart RHJA, de Geus-Oei LF, Stevens J, Elsinga PA, Ivashchenko O, Erba PA. Sex-based differences in nuclear medicine imaging and therapy. Eur J Nucl Med Mol Imaging 2023;50:971-4. [PMID: 36633615 DOI: 10.1007/s00259-023-06113-7] [Reference Citation Analysis]
25 Mei DA, Imberti JF, Vitolo M, Bonini N, Gerra L, Romiti GF, Proietti M, Lip GYH, Boriani G. Single-lead VDD pacing: a literature review on short-term and long-term performance. Expert Rev Med Devices 2023;20:187-97. [PMID: 36755414 DOI: 10.1080/17434440.2023.2178901] [Reference Citation Analysis]
26 Valzania C, Paccagnella A, Spadotto A, Ruotolo I, Bonfiglioli R, Fallani F, Fanti S, Galié N. Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update. J Nucl Cardiol 2023. [PMID: 36855007 DOI: 10.1007/s12350-023-03202-w] [Reference Citation Analysis]
27 Ostan R, Varani S, Giannelli A, Malavasi I, Pannuti F, Pannuti R, Biasco G, Mattioli AV, On Behalf Of The Ant Collaborative Group. Distance Monitoring of Advanced Cancer Patients with Impaired Cardiac and Respiratory Function Assisted at Home: A Study Protocol in Italy. J Clin Med 2023;12. [PMID: 36902706 DOI: 10.3390/jcm12051922] [Reference Citation Analysis]
28 Henry S, Vaidean G, Rege R, Gianos E. Common origins and shared opportunities for breast cancer and cardiovascular disease prevention. Heart 2023:heartjnl-2022-321710. [PMID: 36849236 DOI: 10.1136/heartjnl-2022-321710] [Reference Citation Analysis]
29 Chan JSK, Tang P, Lee TTL, Chou OHI, Lee YHA, Li G, Leung FP, Wong WT, Liu T, Tse G. Association between immune checkpoint inhibitors and myocardial infarction in Asians: A population-based self-controlled case series. Cancer Med 2023. [PMID: 36808819 DOI: 10.1002/cam4.5729] [Reference Citation Analysis]
30 Moya A, Buytaert D, Beles M, Paolisso P, Duchenne J, Huygh G, Langmans C, Roelstraete A, Verstreken S, Goethals M, Dierckx R, Bartunek J, Penicka M, Van Camp G, Heggermont WA, Vanderheyden M. Serial Non-Invasive Myocardial Work Measurements for Patient Risk Stratification and Early Detection of Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients: A Single-Centre Observational Study. J Clin Med 2023;12. [PMID: 36836187 DOI: 10.3390/jcm12041652] [Reference Citation Analysis]
31 Viamonte SG, Joaquim A, Alves A, Vilela E, Capela A, Ferreira C, Costa AJ, Teixeira M, Duarte B, Rato N, Tavares A, Santos M, Ribeiro F. Adherence, safety, and satisfaction of a cardio-oncology rehabilitation program framework versus community exercise training for cancer survivors: findings from the CORE trial. Support Care Cancer 2023;31:173. [PMID: 36800020 DOI: 10.1007/s00520-023-07638-1] [Reference Citation Analysis]
32 Mauro C, Capone V, Cocchia R, Cademartiri F, Riccardi F, Arcopinto M, Alshahid M, Anwar K, Carafa M, Carbone A, Castaldo R, Chianese S, Crisci G, D'Assante R, De Luca M, Franzese M, Galzerano D, Maffei V, Marra AM, Mazza A, Ranieri B, D'Agostino A, Rega S, Romano L, Scagliarini S, Sepe C, Vriz O, Izzo R, Cittadini A, Bossone E, Salzano A. Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways. J Clin Med 2023;12. [PMID: 36836147 DOI: 10.3390/jcm12041612] [Reference Citation Analysis]
33 Couch LS, Lyon AR, López-Fernández T. Cardio-oncology: a new field requiring guidance. Eur Heart J Cardiovasc Imaging 2023;24:e47. [PMID: 36572979 DOI: 10.1093/ehjci/jeac250] [Reference Citation Analysis]
34 Fioretti AM, Leopizzi T, La Forgia D, Scicchitano P, Oreste D, Fanizzi A, Massafra R, Oliva S. Incidental right atrial mass in a patient with secondary pancreatic cancer: A case report and review of literature. World J Clin Cases 2023; 11(5): 1206-1216 [DOI: 10.12998/wjcc.v11.i5.1206] [Reference Citation Analysis]
35 Oristrell G, Burcet G, Valente F, Escrivá-De-Romaní S, Arumí M, Ferreira-González I. Treatment of mild asymptomatic cardiotoxicity in early-stage HER 2-positive breast cancer. Is it justified? Rev Esp Cardiol (Engl Ed) 2023:S1885-5857(23)00044-0. [PMID: 36805384 DOI: 10.1016/j.rec.2022.11.014] [Reference Citation Analysis]
36 van Dalen EC, Leerink JM, Kremer LCM, Feijen EAM. Risk Prediction Models for Myocardial Dysfunction and Heart Failure in Patients with Current or Prior Cancer. Curr Oncol Rep 2023. [PMID: 36787043 DOI: 10.1007/s11912-023-01368-7] [Reference Citation Analysis]
37 Chai Y, Jiang M, Wang Y, Liu Q, Lu Q, Tao Z, Wu Q, Yin W, Lu J, Pu J. Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer-The EARLY-MYO-BC study. Front Cardiovasc Med 2023;10:1021937. [PMID: 36844736 DOI: 10.3389/fcvm.2023.1021937] [Reference Citation Analysis]
38 Mingrone G, Astarita A, Colomba A, Catarinella C, Cesareo M, Airale L, Paladino A, Leone D, Vallelonga F, Bringhen S, Gay F, Veglio F, Milan A. Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience. Cancers (Basel) 2023;15. [PMID: 36831492 DOI: 10.3390/cancers15041149] [Reference Citation Analysis]
39 Hill L, Delgado B, Lambrinou E, Mannion T, Harbinson M, McCune C. Risk and Management of Patients with Cancer and Heart Disease. Cardiol Ther 2023. [PMID: 36757637 DOI: 10.1007/s40119-023-00305-w] [Reference Citation Analysis]
40 Badila E, Japie C, Vrabie AM, Badila A, Georgescu A. Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles. Biomolecules 2023;13. [PMID: 36830690 DOI: 10.3390/biom13020321] [Reference Citation Analysis]
41 Olszyna-Serementa M, Zaborowska-Szmit M, Szmit S, Jaśkiewicz P, Zajda K, Krzakowski M, Kowalski DM. Performance-Status Deterioration during Sequential Chemo-Radiotherapy as a Predictive Factor in Locally Advanced Non-Small Cell Lung Cancer. Curr Oncol 2023;30:2049-60. [PMID: 36826120 DOI: 10.3390/curroncol30020159] [Reference Citation Analysis]
42 Tang M, Wang Y, Cao X, Day JD, Liu H, Sun C, Li G. In-hospital and one-year outcomes in cancer patients receiving percutaneous coronary intervention for acute myocardial infarction: A real-world study. Front Cardiovasc Med 2022;9:1005473. [PMID: 36824290 DOI: 10.3389/fcvm.2022.1005473] [Reference Citation Analysis]
43 Cheng F, Xu Q, Li Q, Cui Z, Li W, Zeng F. Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies. Front Oncol 2023;13:1113462. [PMID: 36814818 DOI: 10.3389/fonc.2023.1113462] [Reference Citation Analysis]
44 Sławiński G, Hawryszko M, Liżewska-Springer A, Nabiałek-Trojanowska I, Lewicka E. Global Longitudinal Strain in Cardio-Oncology: A Review. Cancers (Basel) 2023;15. [PMID: 36765941 DOI: 10.3390/cancers15030986] [Reference Citation Analysis]
45 Astarita A, Mingrone G, Airale L, Cesareo M, Colomba A, Catarinella C, Leone D, Gay F, Bringhen S, Veglio F, Milan A, Vallelonga F. Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study. Cancers (Basel) 2023;15. [PMID: 36765915 DOI: 10.3390/cancers15030955] [Reference Citation Analysis]
46 Mathelin C, Cariou E, Vaysse C. [Will the first european cardio-oncology guidelines change the care pathway for women treated for breast cancer?]. Gynecol Obstet Fertil Senol 2023:S2468-7189(23)00034-X. [PMID: 36738861 DOI: 10.1016/j.gofs.2023.02.002] [Reference Citation Analysis]
47 Potter AS, Hulsukar MM, Wu L, Narasimhan B, Karimzad K, Koutroumpakis E, Palaskas N, Deswal A, Kantharia BK, Wehrens XH. Kinase Inhibitors and Atrial Fibrillation. JACC: Clinical Electrophysiology 2023. [DOI: 10.1016/j.jacep.2022.11.034] [Reference Citation Analysis]
48 Dempke WC, Zielinski R, Winkler C, Silberman S, Reuther S, Priebe W. Anthracycline-induced cardiotoxicity – are we about to clear this hurdle? European Journal of Cancer 2023. [DOI: 10.1016/j.ejca.2023.02.019] [Reference Citation Analysis]
49 Herrmann J, Lpez-Fernndez T, Lyon AR. The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology. Eur Heart J 2023;44:348-50. [PMID: 36587940 DOI: 10.1093/eurheartj/ehac813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Tini G, Tocci G, Battistoni A, Sarocchi M, Pietrantoni C, Russo D, Musumeci B, Savoia C, Volpe M, Spallarossa P. Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies. Curr Heart Fail Rep 2023;20:56-62. [PMID: 36696001 DOI: 10.1007/s11897-023-00590-5] [Reference Citation Analysis]
51 Sase K, Mukai M, Fujiwara Y. Clinical Practice Guidelines in Cardio-Oncology: A Sea of Opportunity. JACC CardioOncol 2023;5:145-8. [PMID: 36875908 DOI: 10.1016/j.jaccao.2022.11.001] [Reference Citation Analysis]
52 Leong DP, Mukherjee SD. The European Society of Cardiology Cardio-Oncology Guidelines: Evidence Base, Actionability, and Relevance to Clinical Practice. JACC CardioOncol 2023;5:137-40. [PMID: 36875915 DOI: 10.1016/j.jaccao.2022.10.009] [Reference Citation Analysis]
53 Farmakis D, Papingiotis G, Filippatos G. Genetic Predisposition to Cardiovascular Disease in Patients With Cancer. JACC: CardioOncology 2023. [DOI: 10.1016/j.jaccao.2022.12.008] [Reference Citation Analysis]
54 Fradley MG. Heart Failure in Patients With Cancer Treated With Anthracyclines-Revisiting the Foundation of Cardio-Oncology. JAMA Netw Open 2023;6:e2254677. [PMID: 36735260 DOI: 10.1001/jamanetworkopen.2022.54677] [Reference Citation Analysis]
55 Cheng RK, Ky B. The ESC 2022 Cardio-Oncology Guidelines and the Road Ahead in Cardio-Oncology. JACC CardioOncol 2023;5:131-2. [PMID: 36875902 DOI: 10.1016/j.jaccao.2022.11.013] [Reference Citation Analysis]
56 Velusamy R, Nolan M, Murphy A, Thavendiranathan P, Marwick TH. Screening for Coronary Artery Disease in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2023;5:22-38. [PMID: 36875910 DOI: 10.1016/j.jaccao.2022.12.007] [Reference Citation Analysis]
57 Zheng H, Zhan H. Cardio-Oncology Guidelines and Strength of the Evidence. JACC CardioOncol 2023;5:149-52. [PMID: 36875914 DOI: 10.1016/j.jaccao.2022.12.001] [Reference Citation Analysis]
58 Averbuch T, Mamas MA, Van Spall HGC. Predicting Risk of Cardiotoxic Effects in Breast Cancer: Are We There Yet? JAMA Netw Open 2023;6:e230577. [PMID: 36821117 DOI: 10.1001/jamanetworkopen.2023.0577] [Reference Citation Analysis]
59 Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, Dimopoulos MA, Kastritis E, Stamatelopoulos K. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2023;5:1-21. [PMID: 36875897 DOI: 10.1016/j.jaccao.2022.12.005] [Reference Citation Analysis]
60 Witteles RM, Reddy SA. ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening? JACC CardioOncol 2023;5:133-6. [PMID: 36875904 DOI: 10.1016/j.jaccao.2022.10.008] [Reference Citation Analysis]
61 Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, Scott CG, Thompson CA, Cerhan JR, Haddad TC, Goetz MP, Herrmann J, Villarraga HR. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010. JAMA Netw Open 2023;6:e2254669. [PMID: 36735254 DOI: 10.1001/jamanetworkopen.2022.54669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
62 Tse G, Shao Q, Liu J, Zhang Y. The Potential Impact of the 2022 ESC Cardio-Oncology Guidelines on Clinical Practice in China. JACC CardioOncol 2023;5:153-5. [PMID: 36875905 DOI: 10.1016/j.jaccao.2023.01.003] [Reference Citation Analysis]
63 Michel L, Totzeck M, Rassaf T. [2022 ESC guidelines on cardio-oncology : Understanding and treating cardiovascular side effects from cancer therapy]. Herz 2023;48:15-22. [PMID: 36441175 DOI: 10.1007/s00059-022-05149-z] [Reference Citation Analysis]
64 Mihalcea D, Memis H, Mihaila S, Vinereanu D. Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors. Life (Basel) 2023;13. [PMID: 36836722 DOI: 10.3390/life13020366] [Reference Citation Analysis]
65 Himeno M, Nagatomo Y, Miyauchi A, Sakamoto A, Kiyose K, Yukino-Iwashita M, Kawai A, Naganuma T, Maekawara S, Naito A, Kagami K, Yumita Y, Yasuda R, Toya T, Ikegami Y, Masaki N, Adachi T. D-Dimer beyond Diagnosis of Pulmonary Embolism: Its Implication for Long-Term Prognosis in Cardio-Oncology Era. J Pers Med 2023;13. [PMID: 36836459 DOI: 10.3390/jpm13020226] [Reference Citation Analysis]
66 Clerico A, Zaninotto M, Aimo A, Cardinale DM, Dittadi R, Sandri MT, Perrone MA, Belloni L, Fortunato A, Trenti T, Plebani M. Variability of cardiac troponin levels in normal subjects and in patients with cardiovascular diseases: analytical considerations and clinical relevance. Clin Chem Lab Med 2023. [PMID: 36695506 DOI: 10.1515/cclm-2022-1285] [Reference Citation Analysis]
67 Imberti JF, Maisano A, Rampini F, Minnocci M, Bertuglia F, Mantovani M, Cherubini B, Mei DA, Ferrara L, Bonini N, Valenti AC, Vitolo M, Longo G, Boriani G. Cardiovascular Reasons for Access to a Tertiary Oncological Emergency Service: The CARILLON Study. J Clin Med 2023;12. [PMID: 36769610 DOI: 10.3390/jcm12030962] [Reference Citation Analysis]
68 Camilli M, Chiabrando JG, Lombardi M, Del Buono MG, Montone RA, Lombardo A, Crea F, Minotti G. Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis. Cardiooncology 2023;9:8. [PMID: 36698216 DOI: 10.1186/s40959-023-00158-1] [Reference Citation Analysis]
69 Bruhn J, Malmborg M, Garred CH, Ravn P, Zahir D, Andersson C, Gislason G, Torp-Pedersen C, Kragholm K, Fosbol E, Butt JH, Lang NN, Petrie MC, McMurray J, Kober L, Schou M. Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. Eur Heart J 2023:ehac797. [PMID: 36691953 DOI: 10.1093/eurheartj/ehac797] [Reference Citation Analysis]
70 Tlegenova Z, Balmagambetova S. Comments on new 2022 European Society of Cardiology guidelines on cardioncology. HVT 2023;0. [DOI: 10.24969/hvt.2023.370] [Reference Citation Analysis]
71 Lee ARYB, Yau CE, Low CE, Li J, Tyebally SM, Lin W, Tan LL, Liao CT, Chang WT, Lee MX, Koo CY, Sia CH. Natural Progression of Left Ventricular Function following Anthracyclines without Cardioprotective Therapy: A Systematic Review and Meta-Analysis. Cancers (Basel) 2023;15. [PMID: 36672461 DOI: 10.3390/cancers15020512] [Reference Citation Analysis]
72 Gong K, Yang Y, Shen Y, Liu H, Xie L, Liu J. Successful management of a rare case of juvenile giant right ventricular myxoma. Front Surg 2022;9:1102742. [PMID: 36713660 DOI: 10.3389/fsurg.2022.1102742] [Reference Citation Analysis]
73 Auberle C, Lenihan D, Gao F, Cashen A. Late cardiac events after allogeneic stem cell transplant: incidence, risk factors, and impact on overall survival. Cardiooncology 2023;9:1. [PMID: 36604733 DOI: 10.1186/s40959-022-00150-1] [Reference Citation Analysis]
74 Mescherina NS, Stepchenko MA, Leontieva TS, Khardikova EM, Mikhailenko TS. Approaches to early diagnosis and prevention of cardiovascular toxicity induced by targeted drugs and immune checkpoint inhibitors in oncohematology: a literature review. Cardiovasc Ther Prev 2023;22:3337. [DOI: 10.15829/1728-8800-2023-3337] [Reference Citation Analysis]
75 Di Lisi D, Madaudo C, Di Fazio L, Gulotta A, Triolo OF, Galassi AR, Incorvaia L, Russo A, Novo G. Higher Incidence of Cancer Therapy-Related Cardiac Dysfunction in the COVID-19 Era: A Single Cardio-Oncology Center Experience. J Cardiovasc Dev Dis 2023;10. [PMID: 36661918 DOI: 10.3390/jcdd10010023] [Reference Citation Analysis]
76 Vasyuk YA, Shupenina EY, Novosel EO, Vyzhigin DA, Nosova AG, Zhukova LG, Filonenko DA, Khatkova EI. Potential of primary drug prevention of cardiotoxicity in the context of anticancer therapy. Russ J Cardiol 2023;27:5258. [DOI: 10.15829/1560-4071-2022-5258] [Reference Citation Analysis]
77 Chan JSK, Ciobanu A, Liu Y, Gkouziouta A, Liu T. Editorial: Novel phenotyping and risk stratification strategies for heart failure. Front Cardiovasc Med 2022;9:1115991. [PMID: 36684557 DOI: 10.3389/fcvm.2022.1115991] [Reference Citation Analysis]
78 Sobiborowicz-Sadowska AM, Kamińska K, Cudnoch-Jędrzejewska A. Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity. Cancers (Basel) 2023;15. [PMID: 36612307 DOI: 10.3390/cancers15010312] [Reference Citation Analysis]
79 Xiao D, Li J, Liu Y, Wang T, Niu C, Zhuang R, Liu B, Ma L, Li M, Zhang L. Emerging trends and hotspots evolution in cardiotoxicity: A bibliometric and knowledge-Map analysis From 2010 to 2022. Front Cardiovasc Med 2023;10:1089916. [PMID: 36960468 DOI: 10.3389/fcvm.2023.1089916] [Reference Citation Analysis]
80 Couch LS, López-Fernández T, Lyon AR. The 'Ten Commandments' for the 2022 European Society of Cardiology guidelines on cardio-oncology. Eur Heart J 2023;44:10-1. [PMID: 36420674 DOI: 10.1093/eurheartj/ehac666] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Camilli M, Maggio L, Tinti L, Lamendola P, Lanza GA, Crea F, Lombardo A. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. Front Cardiovasc Med 2023;10:1090103. [PMID: 36895831 DOI: 10.3389/fcvm.2023.1090103] [Reference Citation Analysis]
82 Dörr R, Maisch B. [2022 ESC Guidelines: new guidelines and new challenges in Europe]. Herz 2023;48:1-2. [PMID: 36723763 DOI: 10.1007/s00059-022-05154-2] [Reference Citation Analysis]
83 Faggiano P, Lorusso R, Carugo S, Faggiano A. Heart Valve Team Conundrum. JACC: Advances 2023;2:100190. [DOI: 10.1016/j.jacadv.2022.100190] [Reference Citation Analysis]
84 Liu Y, Zheng L, Cai X, Zhang X, Ye Y. Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. Front Cardiovasc Med 2023;10:1078135. [PMID: 36910540 DOI: 10.3389/fcvm.2023.1078135] [Reference Citation Analysis]
85 Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023;61:2200879. [PMID: 36028254 DOI: 10.1183/13993003.00879-2022] [Cited by in Crossref: 81] [Cited by in F6Publishing: 33] [Article Influence: 81.0] [Reference Citation Analysis]
86 Tantawy M, Marwan M, Hussien S, Tamara A, Mosaad S. The scale of scientific evidence behind the current ESC clinical guidelines. IJC Heart & Vasculature 2023. [DOI: 10.1016/j.ijcha.2023.101175] [Reference Citation Analysis]
87 Aoshima H, Tawarahara K, Kato H, Ishibashi F, Tokonami Y, Nakamura N, Matsukura G, Kanda T, Ozeki M, Ukigai H, Takeuchi R. Acute Myocardial Infarction Due to Coronary Artery Embolism During Chemotherapy with mFOLFOX-6 Plus Bevacizumab for Metastatic Colon Cancer: A Case Report. Intern Med 2023. [DOI: 10.2169/internalmedicine.0788-22] [Reference Citation Analysis]
88 Oristrell G, Burcet G, Valente F, Escrivá-de-romaní S, Arumí M, Ferreira-gonzález I. Tratamiento de la cardiotoxicidad leve asintomática en cáncer de mama HER2 positivo precoz. ¿Está realmente justificado? Revista Española de Cardiología 2023. [DOI: 10.1016/j.recesp.2022.11.018] [Reference Citation Analysis]
89 Maier RH, Plummer C, Kasim AS, Akhter N, Ogundimu E, Maddox J, Graham J, Stewart M, Wardley A, Haney S, Vahabi S, Oxenham H, Humphreys A, Cresti N, Verrill M, Graham R, Chang L, Hancock HC, Austin D. Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT). BMJ Open 2022;12:e066252. [PMID: 36585130 DOI: 10.1136/bmjopen-2022-066252] [Reference Citation Analysis]
90 Iervolino A, Spadafora L, Spadaccio C, Iervolino V, Biondi Zoccai G, Andreotti F. Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies. Pharmaceutics 2022;15. [PMID: 36678717 DOI: 10.3390/pharmaceutics15010087] [Reference Citation Analysis]
91 Mustapic I, Bakovic D, Susilovic Grabovac Z, Borovac JA. Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction. J Clin Med 2022;12. [PMID: 36614843 DOI: 10.3390/jcm12010042] [Reference Citation Analysis]
92 Ahn Y, Jung MH. Cardiovascular health is the essential but overlooked aspect in the management of cancer survivors. Eur J Prev Cardiol 2022;29:2322-3. [PMID: 36256686 DOI: 10.1093/eurjpc/zwac241] [Reference Citation Analysis]
93 Tamura Y, Tamura Y, Takemura R, Yamada K, Taniguchi H, Iwasawa J, Yada H, Kawamura A. Longitudinal Strain and Troponin I Elevation in Patients Undergoing Immune Checkpoint Inhibitor Therapy. JACC CardioOncol 2022;4:673-85. [PMID: 36636435 DOI: 10.1016/j.jaccao.2022.10.007] [Reference Citation Analysis]
94 Thuny F, Bonaca MP, Cautela J. What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis? JACC CardioOncol 2022;4:624-8. [PMID: 36636431 DOI: 10.1016/j.jaccao.2022.06.008] [Reference Citation Analysis]
95 Thavendiranathan P, Sacher A. A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy? JACC CardioOncol 2022;4:670-2. [PMID: 36636452 DOI: 10.1016/j.jaccao.2022.11.010] [Reference Citation Analysis]
96 Merali A, Anwar M, Boyd JM, Mcfarlane T, Daniluk M. Exploration of current pharmacy practice in cardio-oncology: Experiences & perspectives. J Oncol Pharm Pract 2022. [DOI: 10.1177/10781552221145667] [Reference Citation Analysis]
97 Koltsov AV, Tyrenko VV. Cardioprotective effect of thiotriazoline in cancer patients. Russ J Cardiol 2022;28:5304. [DOI: 10.15829/1560-4071-2023-5304] [Reference Citation Analysis]
98 Itzhaki Ben Zadok O, Shiyovich A, Hamdan A, Yeshurun M, Nardi Agmon I, Raanani P, Kornowski R, Shargian L. Anti-immunoglobulin-like transcript 3 induced acute myocarditis-A case report. Front Cardiovasc Med 2022;9:1035569. [PMID: 36568550 DOI: 10.3389/fcvm.2022.1035569] [Reference Citation Analysis]
99 Kirichenko YY, Ilgisonis IS, Levin PA, Belenkov YN. Prognostic value of vascular remodeling parameters in the development of adverse cardiovascular events in patients with gastric cancer. Russ J Cardiol 2022;27:5230. [DOI: 10.15829/1560-4071-2022-5230] [Reference Citation Analysis]
100 Otsu Y, Kata Y, Takayasu H, Inoue S, Kaneko T. Entrectinib-Induced Heart Failure in a Patient With Metastatic Lung Adenocarcinoma: A Case Report. Cureus 2022;14:e32174. [PMID: 36605067 DOI: 10.7759/cureus.32174] [Reference Citation Analysis]
101 Clayton ZS, Ade CJ, Dieli-Conwright CM, Mathelier HM. A bench to bedside perspective on anthracycline chemotherapy-mediated cardiovascular dysfunction: challenges and opportunities. A symposium review. J Appl Physiol (1985) 2022;133:1415-29. [PMID: 36302155 DOI: 10.1152/japplphysiol.00471.2022] [Reference Citation Analysis]
102 Maria ATJ, Delmas C, Coustal C, Palassin P, Roubille F. Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye! Eur J Cancer 2022;177:194-6. [PMID: 36809166 DOI: 10.1016/j.ejca.2022.09.028] [Reference Citation Analysis]
103 Nolan MT, Creati L, Koczwara B, Kritharides L, Lynam J, Lyon AR, Negishi K, Ngo DTM, Thomas L, Vardy J, Sverdlov AL. First European Society of Cardiology Cardio-Oncology Guidelines: A Big Leap Forward for an Emerging Specialty. Heart Lung Circ 2022;31:1563-7. [PMID: 36549840 DOI: 10.1016/j.hlc.2022.11.003] [Reference Citation Analysis]
104 Raschi E, Poluzzi E, Ponti FD. QT prolongation with anticancer drugs: a multimodal issue. The Lancet Oncology 2022;23:e522. [DOI: 10.1016/s1470-2045(22)00622-2] [Reference Citation Analysis]
105 Riccardi M, Sammartino AM, Piepoli M, Adamo M, Pagnesi M, Rosano G, Metra M, von Haehling S, Tomasoni D. Heart failure: an update from the last years and a look at the near future. ESC Heart Fail 2022;9:3667-93. [PMID: 36546712 DOI: 10.1002/ehf2.14257] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
106 Jing W, Wen-jie P, Min P. Oncocardiology: Far beyond the cardiotoxicity. J Cardiol Cardiovasc Med 2022;7:098-099. [DOI: 10.29328/journal.jccm.1001141] [Reference Citation Analysis]
107 Fazzini L, Caggiari L, Deidda M, Onnis C, Saba L, Mercuro G, Cadeddu Dessalvi C. Metabolomic Profiles on Antiblastic Cardiotoxicity: New Perspectives for Early Diagnosis and Cardioprotection. J Clin Med 2022;11. [PMID: 36431222 DOI: 10.3390/jcm11226745] [Reference Citation Analysis]
108 Efentakis P, Andreadou I, Iliodromitis KE, Triposkiadis F, Ferdinandy P, Schulz R, Iliodromitis EK. Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. Int J Mol Sci 2022;23. [PMID: 36430599 DOI: 10.3390/ijms232214121] [Reference Citation Analysis]
109 Muggeo P, Scicchitano P, Muggeo VMR, Novielli C, Giordano P, Ciccone MM, Faienza MF, Santoro N. Assessment of Cardiovascular Function in Childhood Leukemia Survivors: The Role of the Right Heart. Children (Basel) 2022;9. [PMID: 36421180 DOI: 10.3390/children9111731] [Reference Citation Analysis]
110 Wang H, Zi J, Li Q, Sun Y, Zhu L. Case report: A rare case of recurrent right atrial mass dramatically disappeared after anticoagulation. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1066065] [Reference Citation Analysis]
111 Viamonte SG, Joaquim A, Alves A, Vilela E, Capela A, Ferreira C, Costa AJ, Teixeira M, Duarte B, Rato N, Tavares A, Santos M, Ribeiro F. Adherence, safety and satisfaction of a cardio-oncology rehabilitation program framework versus community exercise training for cancer survivors: findings from the CORE trial.. [DOI: 10.21203/rs.3.rs-2213384/v1] [Reference Citation Analysis]
112 Zito C, Manganaro R, Ciappina G, Spagnolo CC, Racanelli V, Santarpia M, Silvestris N, Carerj S. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. Cancers (Basel) 2022;14. [PMID: 36358830 DOI: 10.3390/cancers14215403] [Reference Citation Analysis]
113 Mampaey G, Hellemans A, de Rooster H, Schipper T, Abma E, Broeckx BJG, Daminet S, Smets P. Assessment of Cardiotoxicity after a Single Dose of Combretastatin A4-Phosphate in Dogs Using Two-Dimensional Speckle-Tracking Echocardiography. Animals 2022;12:3005. [DOI: 10.3390/ani12213005] [Reference Citation Analysis]
114 Harada Y, Shimada K, Harada SJ, Sato T, Kubota Y, Yamashita M. Iodine-123 β-methyl-P-iodophenyl-pentadecanoic Acid (123I-BMIPP) Myocardial Scintigraphy for Breast Cancer Patients and Possible Early Signs of Cancer-Therapeutics-Related Cardiac Dysfunction (CTRCD). J Imaging 2022;8:296. [DOI: 10.3390/jimaging8110296] [Reference Citation Analysis]
115 Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43:3618-731. [PMID: 36017548 DOI: 10.1093/eurheartj/ehac237] [Cited by in Crossref: 143] [Cited by in F6Publishing: 116] [Article Influence: 143.0] [Reference Citation Analysis]
116 Cardinale D, Mills NL, Mueller C. Cardiac biomarkers in the field of cardio-oncology. European Heart Journal. Acute Cardiovascular Care 2022. [DOI: 10.1093/ehjacc/zuac126] [Reference Citation Analysis]
117 Yousif LI, Tanja AA, de Boer RA, Teske AJ, Meijers WC. The role of immune checkpoints in cardiovascular disease. Front Pharmacol 2022;13:989431. [DOI: 10.3389/fphar.2022.989431] [Reference Citation Analysis]
118 Mędrek S, Szmit S. Echocardiography-Assessed Changes of Left and Right Ventricular Cardiac Function May Correlate with Progression of Advanced Lung Cancer-A Generating Hypothesis Study. Cancers (Basel) 2022;14. [PMID: 36230693 DOI: 10.3390/cancers14194770] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Achim A, Liblik K, Gevaert S. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price. Trends Cardiovasc Med 2022:S1050-1738(22)00121-9. [PMID: 36152788 DOI: 10.1016/j.tcm.2022.09.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
120 Ahmed T, Marmagkiolis K, Ploch M, Irizarry-caro JA, Amatullah A, Desai S, Aziz MK, Yarrabothula A, Fossas-espinosa J, Koutroumpakis E, Hassan S, Karimzad K, Kim P, Cilingiroglu M, Iliescu C. The year in Cardio-oncology 2022. Current Problems in Cardiology 2022. [DOI: 10.1016/j.cpcardiol.2022.101435] [Reference Citation Analysis]